Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis

Hepatology

Volumn 55, Issue 2, 2012, Pages 429-436

  Molloy, Jeffrey W ^a   Calcagno, Christopher J ^b   Williams, Christopher D ^a   Jones, Frances J ^a   Torres, Dawn M ^c   Harrison, Stephen A ^a  

^a WILFORD HALL MEDICAL CENTER   (United States)

^b BROOKE ARMY MEDICAL CENTER   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CAFFEINE; HEMOGLOBIN A1C;

ADULT; ARTICLE; BODY MASS; COFFEE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; FLUID INTAKE; HISTOPATHOLOGY; HUMAN; LIVER FIBROSIS; MALE; NONALCOHOLIC FATTY LIVER; PREVALENCE; PRIORITY JOURNAL; RACE;

AGE FACTORS; ALANINE TRANSAMINASE; BODY MASS INDEX; CAFFEINE; COFFEE; FATTY LIVER; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; LIVER; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; SEX FACTORS;

EID: 84856381801     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24731     Document Type: Article

References (32)

1. Klatsky A, Armstrong M. Alcohol, smoking, coffee, and cirrhosis. Am J Epidemiol 1992; 136: 1248-1257.
2. Casiglia E, Spolaore P, Ginocchio G, Ambrosio G. Unexpected effects of coffee consumption on liver enzymes. Eur J Epidemiol 1993; 9: 293-297.
3. Corrao G, Zambon A, Bagnardi V, D'Amicis A, Klastky A. Coffee, caffeine, and the risk of liver cirrhosis. Ann Epidemiol 2001; 11: 458-465.
4. Klatsky A, Morton C, Udaltsova N, Friedman G. Coffee, cirrhosis, and transaminase enzymes. Arch Intern Med 2006; 166: 1190-1195.
5. Gallus S, Tavani A, Negri E, La Vecchia C. Does coffee protect against liver cirrhosis? Ann Epidemiol 2001; 12: 202-205.
6. Tverdal A, Skurtveit S. Coffee intake and mortality from liver cirrhosis. Ann Epidemiol 2003; 13: 419-423.
7. Ruhl E, Everhart J. Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2005; 128: 24-32.
8. Freedman N, Everhart J, Lindsay K, Ghany M, Curton T, Shiffman M, et al. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. HEPATOLOGY 2009; 50: 1360-1369.
9. Modi A, Feldman J, Park Y, Kleiner D, Everhart J, Liang T, et al. Increased coffee consumption is associated with reduced hepatic fibrosis. HEPATOLOGY 2010; 51: 201-209.
10. Gelatti U, Covol L, Franceschini M, Pirali F, Tagger A, Ribero M, et al. Coffee consumption reduces the risk of hepatocellular carcinoma independently of its aetiology: a case control study. J Hepatol 2005; 42: 528-534.
11. Flegal K, Carroll M, Ogden C, Curtin L. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010; 303: 235-241.
12. Browning J, Szczepaniak L, Dobbins R, Nuremberg P, Horton J, Cohen J, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. HEPATOLOGY 2004; 40: 1387-1395.
13. Adams L, Lymp J, St Sauver J, Sanderson S, Lindor K, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-121.
14. Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, et al. Long term follow up of patients with nonalcoholic fatty liver. Clin Gastro Hepatol 2009; 7: 234-238.
15. Ekstedt M, Franzen L, Mathiesen U, Thorelius L, Holmqvist M, Bodemar G, et al. Long term follow up of patients with NAFLD and elevated liver enzymes. HEPATOLOGY 2006; 44: 865-873.
16. Soderberg C, Stal P, Askling J, Glaumann H, Lindberg G, Marmur J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. HEPATOLOGY 2010; 51: 595-602.
17. Williams C, Stengel J, Torres D, Shaw J, Contreras M, Landt C, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140: 124-131.
18. Brunt E, Janney C, DiBisceglie A, Neuschwander-Tetri B, Bacon B. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474.
19. Michels K, Willett W, Fuchs C, Giovannucci E. Coffee, tea, and caffeine consumption and incidence of colon and rectal cancer. J Natl Cancer Inst 2005; 97: 282-292.
20. Gutierrez-Grobe Y, Sanchez-Valle V, Chavez-Tapia NC, Gutierrez-Jimenez AA, Gavilanes-Espinar JG, Kobashi-Margain RA, et al. High coffee intake is associated to lower grade of hepatic steatosis. The role of peripheral antioxidant activity. Abstract 1149, International Liver Congress, Berlin, Germany, March 30-April 3, 2011.
21. Vitaglione P, Morisco F, Mazzone G, Amoruso DC, Ribecco MT, Romano A, et al. Coffee reduces liver damage in a rat model of steatohepatitis: the underlying mechanisms and the role of polyphenols and melanoidins. HEPATOLOGY 2010; 52: 1652-1661.
22. Tillmann H, Suzuki A, Pang H, Dellinger A, Guy CD, Moylan CA, et al. Coffee consumption increases hepatic expression of cytochrome P450s and significantly reduces liver fibrosis in patients with NAFLD. Abstract 776, International Liver Congress, Berlin, Germany, March 30-April 3, 2011.
23. Patel K, Babich M. Efficacy of Vitamin E and Vitamin C in the treatment of nonalcoholic steatohepatitis. Pract Gastroenterol 2010; 5: 20-26.
24. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010; 53: 372-384.
25. Sanyal A, Chalasani N, Kowdley K, McCullough A, Diehl A, Bass N, et al. Pioglitizone, vitamin E, or placebo for nonalcoholic steatohepatitis. NEJM 2010; 362: 1675-1685.
26. Lee K, Mitchell A, Shibamoto T. Antioxidative activities of aroma extracts isolated from natural plants. BioFactors 2000; 13: 173-178.
27. Huber W, Scharf G, Rossmanith W, Prustomersky S, Grasl-Kraupp B, Peter B, et al. The coffee components kahweol and cafestol induce gamma-glutamylcysteine synthetase, the rate limiting enzyme of chemoprotective glutathione synthesis, in several organs of the rat. Arch Toxicol 2002; 75: 685-694.
28. Scharf G, Prustomersky, Huber W. Elevation of glutathione levels by coffee components and its potential mechanisms. Adv Exp Med Biol 2001; 500: 535-539.
29. Schilter B, Perrin I, Cavin C, Hugget A. Placental glutathione S-transferase (GST-P) induction as a potential mechanism for the anti-carcinogenic effect of the coffee-specific components cafestol and kahweol. Carcinogenesis 1996; 17: 2377-2384.
30. Devasagayam T, Kamat J, Mohan H, Kesavan P. Caffeine as an antioxidant: inhibition of lipid peroxidation induced by reactive oxygen species. Biochim Biophys Acta 1996; 1282: 63-70.
31. Lee C. Antioxidant ability of caffeine and its metabolites based on the study of oxygen radical absorbing capacity and inhibition of LDL peroxidation. Clinica Chimica Acta 2000; 295: 141-154.
32. Kalthoff S, Ehmer U, Freiberg N, Manns M, Strassburg C. Coffee induces expression of glucuronosyltransferases via the aryl hydrocarbon receptor and Nrf2 in liver and stomach. Gastroenterology 2010; 139: 1699-1710.